Funding Opportunity RFA-DK-18-515 from the NIH Guide for Grants and Contracts. The Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network conducts multi-center studies of urologic chronic pelvic pain syndrome (UCPPS), a term used to encompass interstitial cystitis/bladder pain syndrome (IC/BPS) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The goal of the MAPP Network is to provide new insights into underlying pathophysiology, natural history, clinical phenotype, and risk factors as a foundation for future clinical intervention efforts and ultimately to improve clinical management. The MAPP Research Network is currently comprised of nine Discovery Sites, a Data Coordination Core (DCC), and a Tissue and Technology Core (TATC). The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to invite an application from the current MAPP Network TATC for an additional three-year project period. During this period, the MAPP Network will continue collection of longitudinal phenotypic data and biological samples from UCPPS participants currently enrolled in the Trans-MAPP Symptoms Patterns Study and continue to conduct highly-collaborative, integrated data analyses for identification of new insights into UCPPS.

Notice NOT-OD-18-229 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-227 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-228 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-18-029 from the NIH Guide for Grants and Contracts. The purpose of this RFA is to support early clinical trials consortia poised to efficiently evaluate the biologic effects of cancer preventive agents and to determine clinically-relevant correlates in order to advance their development for cancer prevention. The program objectives are: To efficiently design and conduct early phase clinical trials to assess the cancer preventive potential of NCI-sponsored agents of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (microdosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials. To characterize the effects of these agents on the molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlate these effects with clinical endpoints. To develop further scientific insights into the mechanism of cancer prevention by the agent examined and continue to develop novel potential markers as determinants of response.

Funding Opportunity RFA-CA-18-030 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a part of the National Cancer Institute (NCI) initiative intended to support Cancer Prevention Clinical Trials Network (CP-CTNet). The goals for the CP-CTNet include: Design and conduct early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (microdosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials; Characterization of the effects of these agents and interventions on their molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlation of these effects with clinical endpoints. Development of further scientific insights into the mechanisms of cancer prevention by the agents examined, including the development of novel potential markers as determinants of response. CP-CTNet consists of two types of components: Five CP-CTNet Sites (covered by companion FOA, RFA-CA-18-029); and One CP-CTNet Data Management, Auditing, and Coordinating Center (DMACC, covered via this FOA). The CP-CTNet Sites will provide scientific leadership in development and conduct of early phase cancer prevention clinical trials as well as manage and analyze the data. The DMACC will support the CP-CTNet Sites and coordinate trans-Network activities with the following specific responsibilities: (i) centralized data management and data reporting, (ii) clinical trials auditing, and (iii) administrative and logistical coordination across CP-CTNet.

Notice NOT-NS-18-092 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-231 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HS-18-002 from the NIH Guide for Grants and Contracts. This initiative will fund the dissemination and implementation of clinical and organizational patient-centered outcomes research (PCOR) findings into primary care practice to improve the delivery of patient-centered approaches to identifying and managing

Funding Opportunity RFA-NS-19-007 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIH Blueprint R25 program is to support educational activities thatenhance the diversity of the biomedical, behavioral and clinical research workforce. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development, Research Experiences, and Mentoring Activities. The fully integrated educational activities should prepare undergraduate students from diverse backgrounds nationally underrepresented in biomedical and behavioral sciences to enter Ph.D. degree programs in the neurosciences. To accomplish this goal, this initiative will provide institutional awards to develop neuroscience research education programs comprised of collaborative partnerships integrated across different educational institution types. Each partnership must include: a) one or more institutions that have substantial enrollment of diverse undergraduates from populations underrepresented in the biomedical and behavioral sciences, b) a research-intensive institution that has an established neuroscience or neuroscience-related program, c) integrated curriculum/academic enhancement and research training activities designed to increase participants' preparation to enter doctoral programs in the neurosciences, and d) well-described plans to provide early communication and interaction between participating students and graduate neuroscience programs across the country.

Notice NOT-CA-18-093 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-18-919 from the NIH Guide for Grants and Contracts. This purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging software tools for planning and validating radiation therapy treatment strategies in clinical trials. The quantitative software tools must have been developed and optimized during a performance period in the Quantitative Imaging Network (QIN) or under other separate funding. The proposed research effort should be an extension of the research that successfully completed the tasks of developing and optimizing the chosen software tools or data collection methods intended to facilitate clinical decision making during clinical trials. This FOA is intended to support the efforts of validating those software tools in prospective multisite clinical trials to test software tool performance and to demonstrate that the software tool can be integrated into clinical workflow with a minimum of disruption.

Funding Opportunity RFA-DK-18-017 from the NIH Guide for Grants and Contracts. The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD. The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD. However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains. The purpose of this Funding Opportunity Announcement (FOA) is to expand the number of genes and range of IBD-related phenotypes and physiological domains under study by means of collaborations of the IBDGC with investigators with expertise complementary to that of their own members. Proposed studies must not duplicate studies either ongoing or already completed by the IBDGC. Multi-site clinical trials will not be considered responsive to this FOA.

Funding Opportunity PA-18-920 from the NIH Guide for Grants and Contracts. The purpose of the National Center for Complementary and Integrative Health (NCCIH) Administrative Supplement to the National Center for Advancing Translational Sciences (NCATS) supported Clinical and Translational Science Awards (CTSA) program is to develop a pipeline of qualified clinician-scientist investigators with complementary and integrative health degrees conducting clinical and/or translational research on complementary interventions for NCCIH high-priority research topics. This funding opportunity announcement (FOA) solicits applications for administrative supplements from awardees of the NCATS supported CTSA programs. Funding for these supplements will be provided by NCCIH.

Notice NOT-AI-18-058 from the NIH Guide for Grants and Contracts

Notice NOT-DA-18-042 from the NIH Guide for Grants and Contracts

Notice NOT-DA-18-043 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-225 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-223 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-224 from the NIH Guide for Grants and Contracts